ABOS vs. OVID, CHMA, EPZM, PRTK, ATHA, RGNX, HLVX, ITOS, TSHA, and VECT
Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Ovid Therapeutics (OVID), Chiasma (CHMA), Epizyme (EPZM), Paratek Pharmaceuticals (PRTK), Athira Pharma (ATHA), REGENXBIO (RGNX), HilleVax (HLVX), iTeos Therapeutics (ITOS), Taysha Gene Therapies (TSHA), and VectivBio (VECT). These companies are all part of the "medical" sector.
Acumen Pharmaceuticals (NASDAQ:ABOS) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.
71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 7.1% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Ovid Therapeutics. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 3 mentions for Ovid Therapeutics. Acumen Pharmaceuticals' average media sentiment score of 1.49 beat Ovid Therapeutics' score of 0.74 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.
Acumen Pharmaceuticals presently has a consensus price target of $12.00, suggesting a potential upside of 308.16%. Ovid Therapeutics has a consensus price target of $8.08, suggesting a potential upside of 164.16%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Acumen Pharmaceuticals is more favorable than Ovid Therapeutics.
Ovid Therapeutics received 326 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. Likewise, 70.55% of users gave Ovid Therapeutics an outperform vote while only 65.52% of users gave Acumen Pharmaceuticals an outperform vote.
Ovid Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Acumen Pharmaceuticals has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
Acumen Pharmaceuticals has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -10,691.14%. Acumen Pharmaceuticals' return on equity of -22.88% beat Ovid Therapeutics' return on equity.
Summary
Ovid Therapeutics beats Acumen Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Acumen Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acumen Pharmaceuticals Competitors List
Related Companies and Tools
